Unadjusted Prognostic effect (n = 1935) and adjusted prognostic effect (n = 1828) of concomitant medications on overall survival (Adjusted for the effect of hemoglobin, ALP,...

MedDRA-compliant description of adverse events (AEs) before CBPP implementation.

List of trials and number of patients (from PDS) used in study analysis.

Incidence rate and adjusted hazard ratio of pulmonary embolism between ACOS and non-ACOS cohorts stratified by sex, age, comorbidity (no/yes), and drug used (no/yes).

Efficacy analyses for primary outcomes (ADAS-Cog 12 and CDR-sb), and the key secondary outcome (DAD).

Characteristics associated with treatment discontinuation among persons experiencing homelessness in 11 US sites from July 2011- June 2015.

Baseline demographics by proportion of days covered (PDC).

Multivariate analyses for citrate accumulation occurrence and duration.

Comparison of grade 3 and 4 AEs for trial participants grouped by baseline and week 24 CLcra.

AccuCirc for early infant male circumcision in Nyanza, Kenya: medical male circumcision information and opinions from mother interviews (n = 700).

Highest degree of pain experienced at various time points (0 = no pain, 10 = worst possible pain).

Baseline Alzheimer disease characteristics.

Summary of patients experiencing AEs (on-treatment) during the entire treatment phase, overall and according to treatment group (12- or >12-week treatment).

Geometric means of pharmacokinetic parameters (Cmax, Cτ, and AUC0–τ) by BMI (≥median versus

Details on switches between bDMARDs.

Ratio of means meta-analysis of the efficacy of placebo group.

Adjusted hazard ratio of pulmonary embolism found in the follow-up period associated with ACOS and prescriptions of ICSs and OSs.

Distribution of maximum toxicity grade experienced by patient across AE categories.

RCT: Randomised controlled trial. GS: Gilead Sciences. R: Roche. GSK: GlaxoSmithKline. NS: not stated. aCopies/mL converted to IU/mL by dividing by 5.bThe limit of detection of...

Characteristics of A. Paniculata used in the included trials.